Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | PKLR | P30613 | 2/20 | 1.00 |
| ▸ | GALNT2 | Q10471 | 2/20 | 1.00 |
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CA7 | P43166 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ellagic Acid SCHEMBL20429 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL30475160 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL1645767 | 1.00 | KDM4E (1.00) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL2639621 | 0.98 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL21590140 | 0.98 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL8686551 | 0.98 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL177722 | 0.98 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL8686557 | 0.98 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL8686700 | 0.98 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 | |
| Ellagic Acid SCHEMBL9146254 | 0.98 | KDM4E (0.96) | KDM4EMAPTHPGDBLMAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120051277-A | R-benzomarirope for the treatment of dyskinesia | 儿童慈善医院 | 2025-05-27 | — | — | CN | claimed |
| CN-119404251-A | Detection of longitudinal progression of Alzheimer's Disease (AD) based on speech analysis | 基因泰克公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119118954-A | Phenylhalyard artificial hapten and artificial antigen as well as preparation methods and application thereof | 杭州同舟生物技术有限公司 | 2024-12-13 | — | — | CN | claimed |
| CN-113286777-B | Compounds, compositions and methods for modulating iron death and treating excitotoxic disorders | 纽约市哥伦比亚大学理事会 | 2024-10-29 | — | — | CN | claimed |
| CN-118666860-A | Preparation process and application of melastoma tomentosa ellagitannin part | 广东药科大学 | 2024-09-20 | — | — | CN | claimed |
| CN-117462481-A | Promoter for promoting nasal delivery of pharmaceutical ingredients and application thereof | 南京星叶生物科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-117120140-A | Methods of treating neurodegenerative disorders with alternating electric fields | 诺沃库勒有限责任公司 | 2023-11-24 | — | — | CN | claimed |
| CN-117120619-A | Compositions and methods for treating neurological disorders associated with a deficiency in glucosylceramidase beta | 沃雅戈治疗公司 | 2023-11-24 | — | — | CN | claimed |
| CN-110730781-B | Tetrahydropyridopyrazine modulators of GPR6 | 武田药品工业株式会社 | 2023-05-05 | — | — | CN | claimed |
| CN-122095248-A | Early biomarkers for parkinson's disease | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260002205-A1 | METHOD OF IDENTIFYING ALLOSTERIC BIOSENSOR PROTEINS WITH NEW SPECIFICITIES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250387364-A1 | ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-12-25 | — | — | US | disclosed |
| US-12414932-B2 | Arsinothricin and methods of treating infections using arsinothricin | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| US-20220202763-A1 | ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-06-30 | — | — | US | disclosed |
| CN-114469814-A | Water lily flower extract and preparation method and application thereof | 浙江大学 | 2022-05-13 | — | — | CN | disclosed |
| US-11298335-B2 | Arsinothricin and methods of treating infections using arsinothricin | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-04-12 | — | — | US | disclosed |
| CN-111419791-B | Method for inhibiting generation of oral liquid precipitate | 成都中医药大学 | 2022-04-08 | — | — | CN | disclosed |
| US-20220105017-A1 | TOPICAL MACQUI BERRY FORMULATION | TRACIE MARTYN INT INC (US) | 2022-04-07 | — | — | US | disclosed |
| US-20220031602-A1 | SKIN PERFECTING COSMETIC COMPOSITIONS AND METHODS OF USE | L'OREAL (FR) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002205-A1 | METHOD OF IDENTIFYING ALLOSTERIC BIOSENSOR PROTEINS WITH NEW SPECIFICITIES | RNGTT, PHAX, PURB | KDM4E 3330/4885MAPT 3333/4885HPGD 3573/4885 |
| US-20250387364-A1 | ARSINOTHRICIN AND METHODS OF TREATING INFECTIONS USING ARSINOTHRICIN | ARSA, NAT1, NAA15 | KDM4E 2578/4885MAPT 1454/4885HPGD 3669/4885 |
| US-20220031602-A1 | SKIN PERFECTING COSMETIC COMPOSITIONS AND METHODS OF USE | CUTA, DSG1, SMURF1 | KDM4E 327/4885MAPT 1248/4885HPGD 2858/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | KDM4E 518/4885MAPT 523/4885HPGD 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.